Prostate adenocarcinoma · line 2 · Cabazitaxel (mCRPC, 2L)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-CABAZITAXEL-MCRPC |
| ID | IND-PROSTATE-MCRPC-2L-CABAZITAXEL |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-PROSTATE |
| Sources | SRC-CARD-DE-BONO-2019 SRC-TROPIC-DE-BONO-2010 |
Used By
Algorithms
ALGO-PROSTATE-MCRPC-2L- ALGO-PROSTATE-MCRPC-2L
Handbook Chapters
HB-PROSTATE-MCRPC-1L- Metastatic castration-resistant prostate cancer: biomarker and sequencing reasoning
Indication
IND-PROSTATE-MCRPC-2L-DOCETAXEL- IND-PROSTATE-MCRPC-2L-DOCETAXELIND-PROSTATE-MCRPC-2L-LU-PSMA- IND-PROSTATE-MCRPC-2L-LU-PSMAIND-PROSTATE-MCRPC-2L-RADIUM223- IND-PROSTATE-MCRPC-2L-RADIUM223